Premium
A clinical trial of the oral form of 4′‐demethyl‐epipodophyllotoxin‐β‐D ethylidene glucoside (NSC 141540) VP 16–213
Author(s) -
Falkson Geoffrey,
Van Dyk J. J.,
Van Eden E. B.,
Van Der Merwe A. M.,
Van Den Bergh J. A.,
Falkson H. C.
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197504)35:4<1141::aid-cncr2820350418>3.0.co;2-3
Subject(s) - medicine , glucoside , clinical trial , pharmacology , stereochemistry , pathology , chemistry , alternative medicine
A clinical trial of the oral form of VP 16‐213 (NSC‐141540), a semisynthetic podophyllotoxin, was undertaken. In 20 patients, treatment was started at 200 mg/day p.o. for 5 days; courses were repeated after a rest period of 16 days. Five patients were treated at the same dose, repeated with only 9‐day rest periods. Subsequently, 65 patients were given 300–400 mg/day for 5 days, with rest periods of 9 days between courses. The side effects encountered included anorexia, nausea and vomiting, stomatitis, diarrhea, leukopenia, throm‐bocytopenia, alopecia, and pruritis. Substernal discomfort with or without palpitations was reported by 18 patients; no explanation for this symptom could be found. No complete remissions (CR) were observed. Partial remissions (PR) and improvement (IMP) were seen as follows: small cell carcinoma, lung (10 patients)—2 PR, 3 IMP; adenocarcinoma, lung (4 patients)—1 PR; alveolar cell carcinoma, lung (1 patient)—1 IMP; mesothelioma (4 patients)—1 IMP; ovarian cancer (12 patients)—3 PR, 3 IMP; breast cancer (20 patients)—4 IMP; colon cancer (8 patients)—2 IMP; bladder cancer (4 patients)—2 IMP; histiocytic lymphoma (7 patients)—2 PR, 3 IMP; chronic myeloid leukemia (1 patient)—1 IMP.